ONCO Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.750

Open

1.465

VWAP

1.50

Vol

2.81M

Mkt Cap

1.09M

Low

1.170

Amount

4.20M

EV/EBITDA(TTM)

--

Total Shares

694.67K

EV

-3.88M

EV/OCF(TTM)

--

P/S(TTM)

2.23

Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.

Show More

Events Timeline

(ET)

2026-03-24

20:00:00

Onconetix Inc Trading Halted, News Pending

2026-02-12 (ET)

2026-02-12

08:30:00

Onconetix Acquires 100% Equity of Realbotix

2025-09-26 (ET)

2025-09-26

08:35:52

Onconetix Secures Funding via Private Placement and Debt Resolution

2025-09-26

08:18:00

Onconetix and Ocuvex mutually agree to terminate merger deal

2025-09-22 (ET)

2025-09-22

08:08:10

Onconetix Grants Manufacturing IP License to Immunovia for Proteomedix

2025-07-16 (ET)

2025-07-16

08:18:34

Onconetix, Ocuvex execute definitive merger agreement

2025-06-16 (ET)

2025-06-16

08:24:51

Onconetix receives positive decision by Nasdaq Hearings Panel

2025-06-11 (ET)

2025-06-11

11:32:50

Onconetix announces 1-for-85 reverse stock split

2025-05-22 (ET)

2025-05-22

16:56:14

Onconetix receives additional delisting notice from Nasdaq

News

stocktwits

03-27stocktwits

What’s Behind the 50% Surge of This Micro-Cap Stock in Premarket Trading?

NASDAQ.COM

03-26NASDAQ.COM

Onconetix Partners with Realbotix for 6G Trial

seekingalpha

03-23seekingalpha

Onconetix Announces 1-for-5 Reverse Stock Split

seekingalpha

02-12seekingalpha

Realbotix Enters All-Stock Acquisition Agreement with Onconetix

moomoo

ANDREW KIGUEL TO ASSUME CEO ROLE OF MERGED COMPANY AFTER CLOSURE, SAYS ONCONETIX INC.

moomoo

REALBOTIX CORP - ONCONETIX ACQUIRES FULL OWNERSHIP OF REALBOTIX, LLC THROUGH STOCK TRANSACTION

Valuation Metrics

The current forward P/E ratio for Onconetix Inc (ONCO.O) is -0.00, compared to its 5-year average forward P/E of -2.37. For a more detailed relative valuation and DCF analysis to assess Onconetix Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.37

Current PE

-0.00

Overvalued PE

6.01

Undervalued PE

-10.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-2.41

Current EV/EBITDA

-0.06

Overvalued EV/EBITDA

7.09

Undervalued EV/EBITDA

-11.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

10.44

Current PS

0.00

Overvalued PS

50.69

Undervalued PS

-29.81

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks that are prime for day trading.

Intellectia · 1075 candidates

Price: $1.00 - $150.00Price Change Pct: $-50.00 - $-0.50Monthly Average Dollar Volume: >= 100,000

Ticker

Name

Market Cap$

Fibrobiologics Inc

13.40M

Viridian Therapeutics Inc

2.80B

Knightscope Inc

71.51M

Origin Materials Inc

19.85M

Fitness Champs Holdings Ltd

2.15M

Onconetix Inc

1.35M

I need all stocks that about to halt?

Intellectia · 22 candidates

Price Change Pct: $-100.00 - $-8.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASENews Driver: Positive, Negative

Ticker

Name

Market Cap$

Iterum Therapeutics PLC

1.90M

Burford Capital Ltd

906.24M

Lantern Pharma Inc

12.53M

Onconetix Inc

1.35M

Amplitech Group Inc

45.60M

Southland Holdings Inc

66.02M

high growth stocks trading under $5

Intellectia · 184 candidates

Price: <= $5.00Annual Eps Yoy Growth: >= 20.0%Annual Revenue Yoy Growth: >= 20.0%

Ticker

Name

Market Cap$

TDH Holdings Inc

10.74M

ReTo Eco-Solutions Inc

2.60M

Iovance Biotherapeutics Inc

1000.00M

Loop Industries Inc

61.87M

Evaxion A/S

26.61M

Onconetix Inc

1.65M

Show me stocks under $2 with growth

Intellectia · 172 candidates

Price: $0.10 - $2.00Annual Eps Yoy Growth: >= 5.0%Annual Revenue Yoy Growth: >= 5.0%

Ticker

Name

Market Cap$

TDH Holdings Inc

11.61M

Geron Corp

871.35M

ReTo Eco-Solutions Inc

3.44M

Loop Industries Inc

55.10M

Onconetix Inc

2.37M

Zentek Ltd

82.63M

Whales Holding ONCO

Trading Trends

People Also Watch

Frequently Asked Questions

What is Onconetix Inc (ONCO) stock price today?

The current price of ONCO is 1.57 USD — it has decreased -19.07

What is Onconetix Inc (ONCO)'s business?

Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.

What is the price predicton of ONCO Stock?

Wall Street analysts forecast ONCO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONCO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Onconetix Inc (ONCO)'s revenue for the last quarter?

Onconetix Inc revenue for the last quarter amounts to 303.60K USD, decreased -57.36

What is Onconetix Inc (ONCO)'s earnings per share (EPS) for the last quarter?

Onconetix Inc. EPS for the last quarter amounts to 3.61 USD, decreased -101.23

How many employees does Onconetix Inc (ONCO). have?

Onconetix Inc (ONCO) has 2 emplpoyees as of March 31 2026.

What is Onconetix Inc (ONCO) market cap?

Today ONCO has the market capitalization of 1.09M USD.